계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
Affymax
company
About
Affymax is a biopharmaceutical company.
- 251 - 500
Highlights
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $20M
- Industries
- Biopharma,Biotechnology,Health Care
- Founded date
- Jan 1, 2001
- Number Of Employee
- 251 - 500
- Operating Status
- Active
Affymax is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions. The company's first product candidate, peginesatide (formerly known as Hematideâ„¢), has been investigated in Phase 3 trials for the potential treatment of anemia associated with chronic kidney disease (CKD). A New Drug Application (NDA) for peginesatide for the treatment of anemia associated with CKD in adult patients on dialysis is currently being reviewed by the U.S. Food and Drug Administration (FDA).
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$80M
Affymax has raised a total of
$80M
in funding over 2 rounds. Their latest funding was raised on
Jul 18, 2005 from a Series D round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jul 18, 2005 | Series D | $60M | 1 |
|
— | Detail |
| Apr 14, 2004 | Series C | $20M | 1 |
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
2
1
Affymax is funded by 1 investors.
Bear Stearns Health Innoventures L.P
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Series D |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
